Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.

This trial has the primary goal to show that BAY68-4986 can lower the ventricular rate in patients with the indication persistent atrial fibrillation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Atrial Fibrillation Arrhythmias, Cardiac Cardiovascular Diseases Heart Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Erfurt, Thuringia, 99084, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Male and/or female (without childbearing potential) white patients
History of persistent or permanent atrial fibrillation
18 to 75 years of age

Exclusion criteria

Patients with high-risk cardiovascular diseases
Stroke or myocardial infarction
Relevant pathological changes in the ECG or echocardiography
Medication affecting ventricular response in Afib

Treatment and study plan

Capadenoson (BAY68-4986)

Drug

4 mg BAY68-4986 for five days

Primary outcomes

The effect of capadenoson (BAY68-4986) on rate control in patients with atrial fibrillation

Time frame: 1 week

Secondary outcomes

To investigate safety and tolerability of this treatment with capadenoson

Time frame: 2 weeks

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Registry information

Official study title

Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation by Administration of Capadenoson in a Dose of 4 mg Once Daily for Five Days

Important dates

Study start: 2008
Primary completion: 2008
Study completion: 2008
First posted: Dec 6, 2007
Registry last updated: Oct 29, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed